Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $-4,690,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 156
- Avg volume
- 5,686
- Day's range
- $0.51 – $0.51
- Shares out
- —
- Stochastic %K
- 87%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is hea...
Show more
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 422 7515
- Website
- https://www.semnurpharma.com
- Address
- 960 San Antonio Road, Palo Alto, United States
Latest news
No headlines yet.
